全文获取类型
收费全文 | 1030篇 |
免费 | 102篇 |
专业分类
儿科学 | 105篇 |
妇产科学 | 51篇 |
基础医学 | 116篇 |
口腔科学 | 21篇 |
临床医学 | 91篇 |
内科学 | 256篇 |
皮肤病学 | 10篇 |
神经病学 | 95篇 |
特种医学 | 20篇 |
外科学 | 79篇 |
综合类 | 9篇 |
一般理论 | 1篇 |
预防医学 | 127篇 |
眼科学 | 7篇 |
药学 | 52篇 |
肿瘤学 | 92篇 |
出版年
2021年 | 12篇 |
2020年 | 13篇 |
2018年 | 23篇 |
2017年 | 15篇 |
2016年 | 13篇 |
2015年 | 17篇 |
2014年 | 19篇 |
2013年 | 27篇 |
2012年 | 47篇 |
2011年 | 39篇 |
2010年 | 20篇 |
2009年 | 14篇 |
2008年 | 29篇 |
2007年 | 20篇 |
2006年 | 23篇 |
2005年 | 28篇 |
2004年 | 33篇 |
2003年 | 24篇 |
2002年 | 26篇 |
2001年 | 27篇 |
2000年 | 27篇 |
1999年 | 40篇 |
1998年 | 16篇 |
1997年 | 19篇 |
1993年 | 15篇 |
1992年 | 31篇 |
1991年 | 24篇 |
1990年 | 19篇 |
1989年 | 16篇 |
1988年 | 21篇 |
1987年 | 23篇 |
1986年 | 19篇 |
1985年 | 27篇 |
1984年 | 12篇 |
1983年 | 13篇 |
1982年 | 21篇 |
1981年 | 12篇 |
1979年 | 22篇 |
1978年 | 20篇 |
1977年 | 17篇 |
1976年 | 18篇 |
1974年 | 18篇 |
1973年 | 13篇 |
1972年 | 19篇 |
1971年 | 16篇 |
1970年 | 16篇 |
1969年 | 22篇 |
1968年 | 13篇 |
1967年 | 13篇 |
1966年 | 11篇 |
排序方式: 共有1132条查询结果,搜索用时 15 毫秒
991.
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X 总被引:1,自引:0,他引:1
C H Pui R K Dodge A T Look S L George G K Rivera M Abromowitch J Ochs W E Evans W M Crist J V Simone 《Journal of clinical oncology》1991,9(8):1341-1347
We studied the frequency, causes, and predictors of adverse events in 624 patients who had completed treatment for acute lymphoblastic leukemia (ALL) in three consecutive total therapy studies (VII, IX, and X, 1972 to 1983). Event-free survival in study X was significantly better overall than that in studies VIII and IX (P less than .0001 by the log-rank test). In study X, 75% of the patients were electively taken off therapy, compared with 54% in studies VIII and IX. However, the risks of having an adverse event during the first 5 years after completion of therapy were remarkably similar: 22% (95% confidence interval, 17% to 29%) in study X versus 24% (20% to 29%) in studies VIII and IX. Bone marrow, testicular, and CNS relapses accounted for the majority of failures in both groups (85% in study X and 92% in studies VIII and IX). Late adverse events consisted largely of hematologic relapses and the development of solid tumors. Black race (P = .001) and leukemia without an anterior mediastinal mass (P = .05) were associated with an increased risk of failure after completion of treatment in the two earlier clinical trials, whereas a lower leukemic cell DNA content (DNA index less than 1.16) was the only predictor of late treatment failure in the more recent trial (P = .019). None of the other presenting features that were examined (eg, age, leukocyte count, and sex) had value as predictors of late failure. Thus, improved treatment altered the impact of specific prognostic factors and the distribution of sites of relapse, but it did not significantly affect the risk of delayed failure. 相似文献
992.
Matthew W. Wood Henry W. Dodge Jr. Einer W. Johnson Jr. Donald W. Mulder 《Postgraduate medicine》2013,125(4):403-409
“If thou examinest a man having a gaping wound in his head, penetrating to the bone and perforating his skull;… shouldst thou find him unable to look at his two shoulders and his breast, and suffering with stiffness in his neck,…” The Edwin Smith Surgical Papyrus.1 相似文献
993.
Neurotoxicity developed in 22 of 97 children and adolescents with malignant solid tumors treated within a phase II ifosfamide protocol. The occurrence of neurotoxicity was related to previous cumulative dosages of cisplatin. One third of the patients who had received more than 600 mg/m2 of cisplatin developed this complication. The relative risk increased 3.2-fold with previous cisplatin dosages above 301 to 600 mg/m2, and 4.1-fold with dosages of 601 to 1,340 mg/m2. The increased risk of neurotoxicity in patients who had received more than 600 mg/m2 of cisplatin may be related to either a decreased clearance of ifosfamide itself or of the drug's active metabolites. 相似文献
994.
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer 总被引:29,自引:0,他引:29
A Berchuck A Kamel R Whitaker B Kerns G Olt R Kinney J T Soper R Dodge D L Clarke-Pearson P Marks 《Cancer research》1990,50(13):4087-4091
Previous studies have suggested that overexpression of HER-2/neu oncogene occurs in 15-40% of breast cancers and that overexpression is associated with poor prognosis. In the present report, we have used an immunohistochemical technique involving a monoclonal antibody specifically reactive with the external domain of HER-2/neu to study expression of HER-2/neu in frozen sections of normal ovary and advanced epithelial ovarian cancer. The intensity of staining for HER-2neu was always moderate or less (0-2+) in normal ovarian epithelium. Among 73 ovarian cancers, 50 (68%) had staining similar to that for normal ovarian epithelium (0-2+) while 23 (32%) stained heavily (3+). Survival of the 23 patients with high HER-2/neu expression (median, 15.7 months) was significantly worse (P = 0.001) than that of the 50 patients (median, 32.8 months) with normal HER-2/neu expression. In addition, patients whose tumors had high HER-2/neu expression were significantly less likely to have a complete response to primary therapy (P less than 0.05) or have a negative second-look laparotomy when serum CA 125 levels were normal preoperatively (P less than 0.05). These findings suggest that HER-2/neu deserves further evaluation as a prognostic marker in epithelial ovarian cancer. 相似文献
995.
996.
997.
G C Rodriguez J T Soper A Berchuck J Oleson R Dodge G Montana D L Clarke-Pearson 《Journal of clinical oncology》1992,10(10):1553-1560
PURPOSE: Recent reports suggest an increasing incidence of CNS metastases in patients with ovarian cancer. We reviewed our experience in the management of brain metastases from ovarian carcinoma and merged our results with those of several other series reported in the literature to determine prognostic factors and the role of chemotherapy, radiation therapy, and surgery. PATIENTS AND METHODS: From 1977 to 1990, 15 of 795 patients who were treated for epithelial ovarian cancer at Duke University developed brain metastases. Fourteen of the patients were treated for their brain metastases; this included radiation therapy (RT; four), surgery and RT (one), RT and systemic chemotherapy (six), and all three treatment modalities (three). A meta-analysis was performed that combined the data from the current series with those of several recent clinical series that reviewed patients with brain metastases from ovarian carcinoma (67 patients total) to elucidate the impact of treatment and extent of disease on survival. RESULTS: In the current series, median survival (MS) after the diagnosis of brain metastases was 9 months. For the combined series, MS was 5 months. Thirteen patients who were treated with whole-brain RT and systemic chemotherapy (MS, 7 months), 10 patients who were treated with RT and surgery (MS, 10 months), and nine patients who were treated with all three modalities (MS, 16.5 months) had significantly longer survival than 19 patients who were treated with RT alone (MS, 3 months) (P = .05, P = .01, and P < .001, respectively). In a multivariate analysis, the only variable that provided prognostic information was treatment, namely the addition of systemic chemotherapy or surgery to RT for the treatment of brain metastases. CONCLUSION: Multimodal treatment of patients with brain metastases from ovarian cancer can result in significant palliation. 相似文献
998.
Clara R. Dodge Miller W. Keith O'steen Sam A. Deadwyler 《The Journal of comparative neurology》1982,208(2):209-214
Following morphine treatment, an autoradiographic study investigated the uptake of 3H-thymidine by the subependymal cells in the rat brain. 3H-thymidine was administered subcutaneously to adult, male Sprague-Daw-ley rats 30 minutes after saline or morphine (10 mg/kg) injection. The animals were sacrified 1 hour after 3H-thymidine administration. In some experiments the opioid antagonist, naloxone, was given alone 45 minutes before 3H-thymidine or 15 minutes before morphine treatment. Three areas of the subependyma were evaluated in terms of the percentage labeled cells and number of grains per nucleus, and a dorsal-to-ventral gradiant was described. Morphine treatment significantly increased the number of 3H-thymidine labeled subependymal cells and number of grains/nucleus within labeled cells. Examination of the distribution of grains/nucleus showed that morphine-treated animals had significantly more cells labeled with 30 or more grains than did saline-injected controls. Prior administration of naloxone blocked the increased 3H-thymidine uptake in morphine-treated animals but had no significant influence on cell proliferation when administered alone. The data are discussed in terms of morphine's possible dual influence on mechanisms which enhance cell transition from G to S phase and/or which accelerate DNA synthesis once these cells have entered the S phase of cell replication. 相似文献
999.
1000.
On the transduction of visual, mechanical, and chemical stimuli 总被引:1,自引:0,他引:1
F A Dodge 《The International journal of neuroscience》1972,3(1):5-14